The company said NUMETA G13E is indicated for PN administration for neonatal patients when oral or enteral nutrition is impossible, insufficient or contraindicated.
NUMETA addresses an important medical need to support neonatal patients who have acute nutritional requirements by providing a balanced formulation of amino acids (protein), glucose (carbohydrates), lipids (fats) and electrolytes in a triple-chamber system that was pioneered by the company.
According to the company, NUMETA G13E is designed for activation and administration at the point of care and ready-to-use PN may reduce the potential risk of medication errors and associated infections.
NUMETA is designed according to the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)-European Society for Clinical Nutrition and Metabolism (ESPEN) Guidelines for Pediatric Parenteral Nutrition1 to provide well-balanced nutrition that supports the growth of a majority of neonatal and pediatric patients.
The availability of NUMETA builds on Baxter's history of innovative delivery technology designed to address patients' specific medical needs - in this case, the needs of some of the most medically vulnerable," said Scott Luce, Baxter's Global Franchise Head for Specialty Pharmaceuticals.
4) This study, which was conducted in France and Belgium in five neonatal intensive care units (NICU), evaluated NUMETA in 97 preterm infants.
The general contraindications for administering NUMETA as an activated two-chamber container system (with the lipid chamber inactivated for intravenous infusion) are as follows: hypersensitivity to egg, soy or peanut proteins, or to any of the active substances, excipients or components of the container; congenital abnormality of the amino acid metabolism; pathogenically elevated plasma concentrations of sodium, potassium, magnesium, calcium and/or phosphorous; and severe hyperglycemia.
Baxters NUMETA G13E is a well-balanced, ready-to-use formula in a triple-chamber system that simplifies the preparation process for healthcare workers and helps reduce the potential risk to patients of infection and dosing errors, said Brik Eyre, president of Baxter's Hospital Products business.
Baxters NUMETA G13E has Marketing Authorization from the Competent Authorities in 15 Western European countries, including Austria, Belgium, France, Germany, Ireland, Malta Netherlands, Poland, Switzerland, the U.
Baxter offers additional pediatric triple-chamber PN solutions in Europe and select Latin American countries, including NUMETA G16E 500mL for term infants and toddlers (term infants through two years of age); and NUMETA G19E 1,000mL for children and adolescents (2-18 years of age).